 The antibody mediated prevention trials are evaluating the effectiveness of VRC01, 10 mg per kilogram or 30 mg per kilogram, in preventing hiv infection through two models, a pre-exposure PE model based on studies with non-human primates and a five-fold model to account for differences between humans and NHPs. The results suggest that VRC01 may confer positive prevention efficacy, but the quantitative predictions are preliminary due to lack of available data. The models can be used to supplement decisions about advancing MAB regimens to efficacy trials and ranking them by their potential for PE in humans.